BridgeBio Pharma Inc. (BBIO), a biopharmaceutical company focused on genetic diseases, is stepping into a season of high-stakes milestones, where science, strategy, and timing converge. Over the next few months, the company will unveil topline data from three registrational Phase 3 trials, each targeting a distinct rare disease with limited treatment options.
The first arrives on Monday, October 27, when interim results from the FORTIFY study will shed light on BBP-418's potential in Limb-girdle Muscular Dystrophy Type 2I/R9.
For comments and feedback contact: editorial@rttnews.com
September 11, 2026 16:26 ET Consumer prices data was the main news on the economic front in the U.S. this week. In Europe, the latest interest rate decision from the European Central Bank was the focus along with the revised second quarter economic growth data for the euro area. In Asia, the monthly foreign trade data from China drew attention.